Effects of Rivaroxaban on Coagulation Assays in Patients with Small Pulmonary Embolism and Deep Vein Thrombosis in Relation to Body Mass Index

Publish Year: 1398
نوع سند: مقاله ژورنالی
زبان: English
View: 456

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_JCTM-7-3_005

تاریخ نمایه سازی: 20 مهر 1398

Abstract:

Introduction: Rivaroxaban is a new anticoagulant medication for pulmonary thromboembolism (PTE) and deep vein thrombosis (DVT). There are limited data on the effect of body mass index (BMI) on the pharmacokinetics of rivaroxaban. This study aimed to assess the effect of rivaroxaban on coagulation assays in relation to BMI in PTE and DVT patients. Materials and Methods: the present cohort studywas conducted on patients with DVT and PTE who were planned to receive rivaroxaban (15 mg bid). Demographic characteristics, as well as anthropometric measurements, were recorded before the rivaroxaban administration. Prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR) were measured before and after 4-6 days of treatment with rivaroxaban. The data were analyzed using paired t-test and analysis of covariance in SPSS software, version 20 (IBM Inc., Chicago, Il, USA) Results: This study was carried out on 100subjects (i.e., 45 males and 55 females) with the mean age of 38.8±1.7 years. The majority of the subjects (68%) had normal creatinine clearance. The results of the research revealed a significant increase in PT, PT, and INR after the administration of rivaroxaban in both normal-weight and obese subjects (P40 years), gender, and creatinine clearance (i.e., normal and abnormal) groups (P Conclusion: The findings of this study indicated a significant increase in coagulation assays in both normal weight and obese subjects; however, the final PT increment was reduced by BMI.

Authors

Shima Ghahremani

MD, Faculty of Medicine, Mashhad Medical Sciences Branch,Islamic Azad University, Mashhad, Iran

Esmat Asaei

Cardiologist, Department of cardiology, Mashhad Medical Sciences Branch,Islamic Azad University, Mashhad, Iran

Mahmoud Shabestari

Cardiologist, Department of Cardiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Majid Jalalyazdi

Cardiologist, Department of Cardiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015; ...
  • Bĕlohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I: ...
  • Scheres LJ, Lijfering WM, Cannegieter SC. Current and future burden ...
  • Becattini C, Agnelli G. Treatment of venous thromboembolism with new ...
  • Schulman S, Ageno W, Konstantinides SV. Venous thromboembolism: past, present ...
  • Rechenmacher SJ, Fang JC. Bridging anticoagulation: primum non nocere. J ...
  • Weitz JI, Semchuk W, Turpie AG, Fisher WD, Kong C, ...
  • Mueck KM, Putnam LR, Anderson KT, Lally KP, Tsao K, ...
  • Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. ...
  • Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, ...
  • Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement ...
  • van Veen JJ, Smith J, Kitchen S, Makris M. Normal ...
  • Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, ...
  • Pan S, Zhu L, Chen M, Xia P, Zhou Q. ...
  • Krauss ES, Cronin M, Dengler N, Simonson BG, Altner K, ...
  • Sharif-Barfeh Z, Beigoli S, Marouzi S, Rad AS, Asoodeh A, ...
  • Moore KT, Kröll D. Influences of obesity and bariatric surgery ...
  • Tittl L, Endig S, Marten S, Reitter A, Beyer-Westendorf I, ...
  • Executive summary of the clinical guidelines on the identification, evaluation, ...
  • Sanei H, Asoodeh A, Hamedakbari-Tusi S, Chamani J. Multi-spectroscopic investigations ...
  • Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters ...
  • Di Nisio M, Vedovati MC, Riera-Mestre A, Prins MH, Mueller ...
  • Kubitza D, Becka M, Roth A, Mueck W. The influence ...
  • Chamani J, Heshmati M. Mechanism for stabilization of the molten ...
  • Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight ...
  • De Caterina R, Lip GYH. The non-vitamin K antagonist oral ...
  • Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, ...
  • Moosavi-Movahedi AA, Chamani J, Gharanfoli M, Hakimelahi GH. Differential scanning ...
  • Barsam SJ, Patel JP, Roberts LN, Kavarthapu V, Patel RK, ...
  • Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv ...
  • Gerchman F, Tong J, Utzschneider KM, Zraika S, Udayasankar J, ...
  • نمایش کامل مراجع